Molecular Neurodegeneration

Molecular Neurodegeneration is an open access peer-reviewed journal published by BioMed Central, part of Springer Nature, covering all aspects of neurodegeneration research at the molecular and cellular levels. Founded in 2006, it is a leading journal in neuroscience, with a 2025 impact factor of 19.6, indexed in SCIE.《分子神经退行性疾病》（Molecular Neurodegeneration）是由 Springer Nature 旗下 BioMed Central 出版的开放获取同行评审期刊，涵盖分子与细胞层面神经退行性疾病研究的各个方面。该刊创刊于 2006 年，是神经科学领域的领军期刊，2025 年影响因子为 19.6，被 SCIE 收录。

Scope

The journal's stated aim is to publish research that advances understanding of the molecular and cellular mechanisms underlying neurodegeneration, with its official scope covering:刊物官方宗旨为发表增进对神经退行性疾病分子与细胞机制理解的研究，官方声明的征稿范围包括：

• Neurodegenerative diseases: original research on the pathogenesis of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and related disorders.神经退行性疾病： 关于阿尔茨海默病、帕金森病、肌萎缩侧索硬化症、亨廷顿病等神经退行性疾病发病机制的原创研究。
• Molecular and cellular mechanisms: studies on the molecular and cellular mechanisms of neurodegeneration, including protein misfolding and aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammation.分子与细胞机制： 关于神经退行性疾病分子与细胞机制的研究，涵盖蛋白质错误折叠与聚集、线粒体功能障碍、氧化应激与神经炎症等。
• Genetics and epigenetics: work on the genetic and epigenetic basis of neurodegenerative diseases, including disease-associated genes, mutations, and the regulation of gene expression.遗传学与表观遗传学： 关于神经退行性疾病遗传与表观遗传基础的研究，涵盖疾病相关基因、突变与基因表达调控等。
• Therapeutic approaches: research on potential therapeutic targets and strategies for neurodegenerative diseases, including drug development, gene therapy, and neuroprotective approaches.治疗方法： 关于神经退行性疾病潜在治疗靶点与策略的研究，涵盖药物开发、基因治疗与神经保护方法等。
• Article types: original research articles, reviews, methods articles, and short reports covering all aspects of molecular and cellular neurodegeneration research.栏目设置： 接受原创研究论文、综述、方法文章与短篇报道，涵盖分子与细胞神经退行性疾病研究的各个方面。

History

• Founding: Molecular Neurodegeneration was founded in 2006 by BioMed Central, established to provide a dedicated open access forum for molecular and cellular research on neurodegeneration.创刊： 《分子神经退行性疾病》于 2006 年由 BioMed Central 创办，旨在为分子与细胞层面的神经退行性疾病研究提供专门的开放获取论坛。
• BioMed Central and Springer Nature: the journal is published by BioMed Central, which became part of Springer Nature in 2015, maintaining its open access publishing model.BioMed Central 与 Springer Nature： 该刊由 BioMed Central 出版，后者于 2015 年成为 Springer Nature 的一部分，持续其开放获取出版模式。
• Official journal of BrightFocus Foundation: the journal serves as the official journal of the BrightFocus Foundation, a nonprofit organisation supporting research on Alzheimer's disease, glaucoma, and macular degeneration.BrightFocus 基金会官方期刊： 该刊是 BrightFocus 基金会的官方期刊，该基金会为支持阿尔茨海默病、青光眼与黄斑变性研究的非营利组织。
• Open access model: since its founding the journal has been fully open access, with all articles freely available to readers immediately upon publication.开放获取模式： 自创刊以来该刊实行完全开放获取，所有文章发表后即向读者免费开放。

Editors

The journal is led by an editor-in-chief supported by senior editors and an international editorial board:该刊由主编领导，资深编辑与国际编委会协助工作：

• Editor-in-chief: Guojun Bu, PhD, of the Hong Kong University of Science and Technology, serves as editor-in-chief, with research expertise in the molecular and cellular mechanisms of Alzheimer's disease.主编： 香港科技大学卜国军（Guojun Bu）哲学博士担任主编，专长于阿尔茨海默病的分子与细胞机制研究。
• Senior editors: the journal is supported by senior editors with expertise in key areas of neurodegeneration research, including Alzheimer's disease, Parkinson's disease, and motor neuron disease.资深编辑： 该刊由具备神经退行性疾病研究关键领域专长的资深编辑支持，涵盖阿尔茨海默病、帕金森病与运动神经元病等。
• International editorial board: the journal has an international editorial board comprising researchers from leading neuroscience institutions worldwide.国际编委会： 该刊拥有国际编委会，成员来自全球顶尖神经科学机构的研究人员。
• Review model: manuscripts undergo rigorous peer review by external experts in molecular and cellular neuroscience, with editorial decisions based on scientific quality and novelty.评审模式： 稿件由分子与细胞神经科学领域外部专家进行严格同行评审，编辑决定基于科学质量与新颖性做出。